The 17th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) meeting took place at the Steigenberger Airport Hotel on the 13–14 May 2019.
The 2019 IOTOD Scientific Committee headed-up the two-day meeting, with international experts invited to speak on topics such as opioid analgesic dependence (OAD), abstinence-based pathways, overdose prevention, and HIV and HCV.
The webcasts from this year’s conference are available to view below
STRATEGIES FOR EVOLVING POPULATIONS: MAXIMISING NEW APPROACHES AND SHARPENING OLD TOOLS
Dr Ashley Brown discusses the value of improving hepatitis C virus (HCV) screening and treatment uptake for all opioid-dependent patients, from treatment entry and as appropriate throughout their treatment journey.
*The IOTOD educational programme is run at arm’s length from the financial supporters and all content is created by the faculty. No funder has had input into the content of the materials or presentations used in the educational programme. PCM Scientific is the medical education company acting as scientific secretariat and conference organiser.
Camurus is a Swedish research-based pharmaceutical company with more than 25 years of innovation and leadership in lipid-based drug delivery technologies. For the development of new product candidates, Camurus utilises its own patented FluidCrystal® drug delivery technologies. New proprietary medicines with improved properties and better treatment outcomes are developed by combining these technologies with established and regulatory approved active ingredients. Camurus’ development pipeline contains product candidates that address conditions with distinct and important medical needs, such as cancer, endocrine disorders, metabolic disorders, opioid dependence and chronic pain.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways. Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe. For more information visit www.althea.life
Measuring behavioural changes
2011 marked the year measurement of delegate behavioural changes began. These measurements showed the IOTOD conference elicited measurable significant improvements in physician behaviours over the years, which have been published in the European Journal of CME.